New hope for cancer patients forced off immunotherapy due to severe side effects
NCT ID NCT07313202
First seen Jan 07, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This study tests a drug called ivarmacitinib in 72 adults with advanced solid tumors who had to stop immunotherapy because of serious immune-related side effects. The goal is to see if ivarmacitinib can control those side effects and allow some patients to safely restart their cancer treatment. The study has two parts: first, a safety check, then an expansion phase to measure how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED SOLID TUMORS WHO DISCONTINUED TREATMENT DUE TO IRAE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.